|  | Cancer | Leukemia

Disparities in Multiple Myeloma: Race, Gender, Socioeconomics, and Paths to Equity

The Disparity Landscape

Multiple myeloma (MM) is the 2nd most common hematologic malignancy. Disparities persist across the continuum: incidence, diagnosis, treatment, outcomes, survival.

Documented Disparities

DimensionEvidence
Race/EthnicityBlack Americans: 2-3x incidence vs. White. Younger onset (median 66 vs 70). Higher risk MGUS progression. Worse survival despite similar treatment access in equal-access systems (VA).
GenderMale:Female ~1.5:1 incidence. Women: longer survival (estrogen protective?). Different adverse event profiles.
AgeMedian dx 69. <65: more aggressive biology, better tolerance. >75: underrepresented in trials, undertreated, worse outcomes.
Socioeconomic StatusLow SES: later stage, less triplet therapy, lower transplant referral, higher early mortality. Area deprivation index predicts survival.
Geography/AccessRural: fewer hematologists, longer travel, less trial access. Safety-net hospitals: delayed novel therapy adoption.
InsuranceMedicaid/uninsured: later stage, less triplet induction, lower transplant rates, worse survival vs. Medicare/private.

Root Causes: Multilevel

  1. Biological: Genetic ancestry (African ancestry SNPs: higher risk, different cytogenetics e.g., more t(11;14), less hyperdiploidy). Tumor microenvironment differences.
  2. Structural Racism: Redlining → environmental exposures, food deserts, chronic stress → biology. Medical mistrust (Tuskegee legacy).
  3. Healthcare System: Implicit bias, fragmented care, financial toxicity ($150k+/yr), prior authorization delays, trial exclusion criteria (renal, comorbidities disproportionately affect minorities).
  4. Social Determinants: Transportation, caregiving, health literacy, paid leave, nutrition, housing stability.

Strategies for Equity

Systemic / Policy

  • Diverse trial enrollment mandates (FDA guidance)
  • Medicaid expansion + oral parity laws
  • Community health worker navigation programs
  • Telehealth + mobile clinics for rural access
  • Diversity in hematology workforce

Clinical Practice

  • Standardized pathways reduce discretion/bias
  • Proactive social needs screening + resource connection
  • Financial counseling at diagnosis
  • Culturally congruent communication (teach-back, interpreter)
  • Transplant referral triggers (automatic at diagnosis)

Research

  • Ancestry-informed risk models (not just race)
  • Disparities-focused trials (e.g., Myeloma Disparities Research Network)
  • Real-world data from diverse populations

Patient / Community

  • Peer navigators (International Myeloma Foundation, Leukemia & Lymphoma Society)
  • Support groups by/for Black patients, young adults, caregivers
  • Clinical trial finder tools with diversity filters

Progress & Hope

  • Black-white survival gap narrowing in recent SEER data (novel therapy access)
  • Carfilzomib, daratumumab, bispecifics, CAR-T benefit all subgroups
  • MGUS screening in high-risk populations (PROMISE study)

Equity is achievable. It requires intentional design at every level: biology, bedside, boardroom, ballot box.

Leukemia - Related Articles